Citius Pharmaceuticals has entered into an agreement with Dr. Reddy’s Laboratories to acquire its exclusive license of E7777 (denileukin diftitox), a late-stage oncology immunotherapy for the treatment of CTCL, a rare form of non-Hodgkin lymphoma. E7777, an engineered IL-2-diphtheria toxin fusion protein, is an improved formulation of oncology agent, ONTAK, which was previously approved by the U.S. FDA for the treatment of patients with persistent or recurrent CTCL. The last patient in a p...